Liquidia Corp (LQDA) Stock AnalysisLQDAStock AnalysisLiquidia Corp

Liquidia Corporation is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products for cardiopulmonary diseases. The Company operates within the biotechnology sector, focusing on treatments for conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enables precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is a PRINT‑engineered inhaled dry‑powder formulation of treprostinil designed to enhance deep lung delivery, improve therapeutic performance, and enable higher dose administration through a convenient inhaler. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Liquidia Corp (LQDA) is a good buy right now due to its recent strong financial performance, particularly a net income of $74.7 million in Q2 2026, and a significant increase in revenue to $171.7 million, which reflects a strong demand for its product YUTREPIA. Additionally, the stock has a forward P/E ratio of 20.75, indicating potential for growth relative to its earnings. However, the main risk is the recent stock volatility, with a 20% drop following the earnings report, which could indicate market uncertainty.

4 analysts cover LQDA: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 47.50.